Cogstate (ASX:CGS) said that for the fiscal half ended Dec. 31, 2024, it reported total revenue of about AU$23.9 million, an increase of 19% from AU$20.2 million a year earliere, according to a Monday filing with the Australian bourse.

Clinical trials revenue rose 27% to about AU$22.7 million over the same period. Net clinical trials sales contracts executed clocked in at AU$20.3 million, a growth of 86% from the prior corresponding half-year.

It also bought back 1.4 million ordinary shares for a total cost of AU$1.6 million, at an average cost of AU$1.12 per share.

The firm's shares rose almost 5% in recent trading on Monday.